Video of A patient perspective on hepatic encephalopathy (HE)

NEW REAL WORLD STUDY SHOWS RIFAXIMIN-α SIGNIFICANTLY REDUCED HOSPITALISATION IN PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY (HE) WHEN ADDED TO LACTULOSE

Media Contacts

For a further information or an interview with Dr Rosalie C. Oey, Lead Investigator of the study please contact:

Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477

Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883

contact@norgine.com

Follow Us

Website

www.norgine.com